RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more.
| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| rdfs:comment
| - RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more. (en)
- RV 144, é o nome de um ensaio clínico tailandês de uma vacina contra o HIV combinando duas vacinas mais antigas que falharam sozinhas. O teste foi lançado em outubro de 2003, ele testou uma estratégia de combate à infecção de dois tiros usando medicamentos feitos pela Sanofi-Pasteur de Lyon, França, e VaxGen de Brisbane, Austrália. Ao longo de 24 semanas, os participantes receberam quatro doses de uma vacina "primer"; um vírus de aves com deficiência contendo versões sintéticas de três genes do HIV; e duas doses de um "reforço", que consistia em uma proteína chamada gp120, um componente principal do revestimento externo do HIV. Os médicos testaram a infecção pelo HIV a cada 6 meses durante 3 anos. O relatório inicial mostrou que a taxa de infecção por HIV entre os voluntários que receberam (pt)
|
| dcterms:subject
| |
| Wikipage page ID
| |
| Wikipage revision ID
| |
| Link from a Wikipage to another Wikipage
| |
| Link from a Wikipage to an external page
| |
| sameAs
| |
| dbp:wikiPageUsesTemplate
| |
| has abstract
| - RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more. The trial collaborators have stated that results of this trial give the first supporting evidence of any vaccine being effective in lowering the risk of contracting HIV. On October 20, 2009, the organizers released full results of the study through publishing in the New England Journal of Medicine and presented them at the AIDS Vaccine Conference in Paris. (en)
- RV 144, é o nome de um ensaio clínico tailandês de uma vacina contra o HIV combinando duas vacinas mais antigas que falharam sozinhas. O teste foi lançado em outubro de 2003, ele testou uma estratégia de combate à infecção de dois tiros usando medicamentos feitos pela Sanofi-Pasteur de Lyon, França, e VaxGen de Brisbane, Austrália. Ao longo de 24 semanas, os participantes receberam quatro doses de uma vacina "primer"; um vírus de aves com deficiência contendo versões sintéticas de três genes do HIV; e duas doses de um "reforço", que consistia em uma proteína chamada gp120, um componente principal do revestimento externo do HIV. Os médicos testaram a infecção pelo HIV a cada 6 meses durante 3 anos. O relatório inicial mostrou que a taxa de infecção por HIV entre os voluntários que receberam a vacina experimental foi 31% menor do que a taxa de infecção por HIV em voluntários que receberam o placebo. No entanto, a redução não foi grande o suficiente para o Ministério da Saúde da Tailândia apoiar a aprovação da vacina; foi relatado em 2019 que o teria licenciado se a redução fosse de 50% ou mais. Os colaboradores do estudo declararam que os resultados deste estudo forneceram a primeira evidência de apoio de qualquer vacina sendo eficaz na redução do risco de contrair o HIV. Em 20 de outubro de 2009, os organizadores divulgaram os resultados completos do estudo através da publicação no New England Journal of Medicine e os apresentaram na AIDS Vaccine Conference em Paris. (pt)
|
| gold:hypernym
| |
| prov:wasDerivedFrom
| |
| page length (characters) of wiki page
| |
| foaf:isPrimaryTopicOf
| |
| is Link from a Wikipage to another Wikipage
of | |
| is Wikipage redirect
of | |
| is foaf:primaryTopic
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)